Journal
PEPTIDES
Volume 114, Issue -, Pages 29-37Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.peptides.2019.04.005
Keywords
Elabela; Diabetes; Kidney; Podocyte; Apoptosis; PI3K/Akt/mTOR pathway
Funding
- National Natural Science Foundation of China [81600572]
- Science and Technology Development Program funded project of Jilin Province, China [20170520025JH]
Ask authors/readers for more resources
Diabetic nephropathy is a common complication of diabetes characterized by an increased rate of protein excretion in urine and kidney function loss. Elabela is a newly discovered peptide whose role in the regulation of diabetes is the major focus of this research. We established an in vivo model of Type 1 diabetes mellitus by injecting mice intraperitoneally with streptozotocin. The treatment group was administered Elabela for 6 months. In the present study, Elabela administration under diabetic conditions was found to reduce renal inflammation and fibrosis markers, leading to improvement in renal pathology and kidney dysfunction. Furthermore, Elabela acts through the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin signaling pathway and decreases podocyte apoptosis, thereby exhibiting a nephroprotective effect against diabetic nephropathy. Our findings provide the first evidence that Elabela has a potential renoprotective effect in patients of diabetes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available